Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > The China supplier of Anidulafungin AP...

The China supplier of Anidulafungin AP...

pharmaceutical raw materials
The China supplier of Anidulafungin AP... structure

The China supplier of Anidulafungin AP... 

structure

Description

Anidulafungin is a new semisynthetic echinocandin with antifungal potency.


Solid


Anidulafungin is a semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis. It is an azamacrocycle, a heterodetic cyclic peptide, a semisynthetic derivative, an echinocandin and an antibiotic antifungal drug.|Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.|Anidulafungin is an Echinocandin Antifungal.|Anidulafungin is a cyclic lipopeptide echinocandin derivative with antifungal activity. Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. (NCI04)|Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.

The China supplier of Anidulafungin AP... Basic Attributes

1140.25

1139.506348

1806241-263-5

9HLM53094I

C38716

J02AX06|J - Antiinfectives for systemic use

Characteristics

377

2.9

Solid

1.5±0.1 g/cm3

1477°C at 760 mmHg

847.0±34.3 °C

1.688

Practically insoluble

0mmHg at 25°C

Safety Information

|Warning|H302 (99.38%): Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P264, P270, P280, P281, P301+P312, P305+P351+P338, P308+P313, P330, P337+P313, P405, and P501|Aggregated GHS information provided by 160 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day).

84%

Drug Information

For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.|FDA Label|Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.|Treatment of invasive candidiasis

Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against many Candida, as well as some Aspergillus. Like other echinocandins, anidulafungin is not active against Cryptococcus neoformans, Trichosporon, Fusarium, or zygomycetes.

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)

Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized.|30 to 50 L|1 L/h

Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity.

40-50 hours

Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death.

1-((4R,5R)-4,5-Dihydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-L-ornithine)-echinocandin B

The China supplier of Anidulafungin AP... Use and Manufacturing

Uses

nucleoside reverse transcriptase inhibitor (NRTI) for HIV treatment in adults

Human drugs -> Ecalta -> EMA Drug Category|Antimycotics for systemic use -> Human pharmacotherapeutic group|Human Drugs -> EU pediatric investigation plans|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:1140.2
XLogP3:2.3
Hydrogen Bond Donor Count:14
Hydrogen Bond Acceptor Count:17
Rotatable Bond Count:14
Exact Mass:1139.50629389
Monoisotopic Mass:1139.50629389
Topological Polar Surface Area:377
Heavy Atom Count:82
Complexity:2150
Defined Atom Stereocenter Count:15
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of The China supplier of Anidulafungin AP...

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.